With regards to multi‐modal treatment approaches, PI3K/AKT pathway inhibition by means of GDC‐0941 enhances the efficacy of Axitinib against c‐myc‐amplified medulloblastoma. This evidence concerns the gene AKT1 and medulloblastoma.